Azemiglitazone Explained
| Legal Status: | Investigational |
| Synonyms: | Azemiglitazone potassium; MSDC-0602; MSDC-0602K |
| Cas Number: | 1133819-87-0 |
| Pubchem: | 25230266 |
| Unii: | 81MXZ6QOBM |
| Drugbank: | DB16028 |
| Chemspiderid: | 32698412 |
| Chembl: | 4291468 |
| Iupac Name: | 5-4-[2-(3-Methoxyphenyl)-2-oxoethoxy]phenylmethyl]-1,3-thiazolidine-2,4-dione |
| C: | 19 |
| H: | 17 |
| N: | 1 |
| O: | 5 |
| S: | 1 |
| Stdinchi: | 1S/C19H17NO5S/c1-24-15-4-2-3-13(10-15)16(21)11-25-14-7-5-12(6-8-14)9-17-18(22)20-19(23)26-17/h2-8,10,17H,9,11H2,1H3,(H,20,22,23) |
| Stdinchikey: | YAUMOGALQJYOJQ-UHFFFAOYSA-N |
| Smiles: | COC1=CC=CC(=C1)C(=O)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3 |
Azemiglitazone (MSDC-0602) is a novel insulin sensitizer designed to retain the effect of thiazolidinediones on mitochondrial pyruvate carriers with limited PPAR-gamma binding. It is hoped to have fewer adverse effects than the thiazolidinediones and is being developed by Cirius Therapeutics for type 2 diabetes and non-alcoholic fatty liver disease.[1] [2] [3] It is formulated as its potassium salt, azemiglitazone potassium (MSDC-0602K).
Notes and References
- Colca . Jerry R. . Lee . Bo Hyun . Iwashita . Julie S. . Dittrich . Howard C. . Harrison . Stephen A. . 1090-P: MSDC-0602k, a New Oral Insulin Sensitizer in Insulin Resistant NASH Patients with and without Type 2 Diabetes (T2D) . Diabetes . 1 June 2020 . 69 . Supplement_1 . 10.2337/db20-1090-P. 225824217 .
- Harrison . Stephen A. . Alkhouri . Naim . Davison . Beth A. . Sanyal . Arun . Edwards . Christopher . Colca . Jerry R. . Lee . Bo Hyun . Loomba . Rohit . Cusi . Kenneth . Kolterman . Orville . Cotter . Gad . Dittrich . Howard C. . Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study . Journal of Hepatology . April 2020 . 72 . 4 . 613–626 . 10.1016/j.jhep.2019.10.023. 31697972 .
- Kamm . Dakota R. . Pyles . Kelly D. . Sharpe . Martin C. . Healy . Laura N. . Colca . Jerry R. . McCommis . Kyle S. . Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide . Journal of Biological Chemistry . January 2021 . 296 . 100807 . 10.1016/j.jbc.2021.100807. 34022222 . 8192871 . free .
